AI assistant
EARNZ PLC — Capital/Financing Update 2018
Oct 10, 2018
7609_rns_2018-10-10_454ae29b-096a-4eba-9a91-bac1b2d2b6ea.html
Capital/Financing Update
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 5991D
Verditek PLC
10 October 2018
Verditek PLC
("Verditek" or the "Company")
Update on Convertible Loan Note
Verditek plc, (AIM: VDTK), the clean technology company, announces that further to its announcements of 21 August and 19 September 2018 in relation to the issue of the Convertible Loan Note, it has received funds and holds bank transfer instructions for a total of £500,000. It expects to receive further funds in the next few days in settlement of the issue of the Convertible Loan Note for which it has received subscription commitments for a total in excess of £2.5 million. A further announcement will be made once settlement has completed.
Enquiries:
Verditek plc
Geoffrey Nesbitt, CEO +44 (0) 20 7129 1110
Stockdale Securities Limited (NOMAD and Broker)
Antonio Bossi / David Coaten +44 (0) 20 7601 6100
Strand Hanson Limited (Financial Adviser)
James Harris / Ritchie Balmer / Jack Botros +44 (0) 20 7409 3494
Whiteoaks International
Mary Fitzgerald +44 (0) 7795 284440
Bekki Bushnell +44 (0) 7841 698586
About Verditek
Verditek plc (AIM: VDTK), the clean technology company is headquartered in London. Verditek is dedicated to commercialising proven technology that can deliver significant competitive advantage compared to conventional industrial solutions. From light-weight solar modules, cutting edge de-odourisation, and ground-breaking CO2 capture, Verditek is realising tomorrow's technologies today.
For further information, please visit www.verditek.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
MSCFFFFSSFASESS